Health and Fitness Health and Fitness
Wed, August 22, 2012
[ Wed, Aug 22nd 2012 ] - Market Wire
Inergetics Shareholder Update
Tue, August 21, 2012
Mon, August 20, 2012
[ Mon, Aug 20th 2012 ] - Market Wire
Watson Launches Generic Xopenex
Sat, August 18, 2012
Fri, August 17, 2012
Thu, August 16, 2012
Wed, August 15, 2012
Tue, August 14, 2012
Mon, August 13, 2012
Fri, August 10, 2012
Thu, August 9, 2012
Wed, August 8, 2012
Tue, August 7, 2012
Mon, August 6, 2012
Fri, August 3, 2012
Thu, August 2, 2012
[ Thu, Aug 02nd 2012 ] - Market Wire
00 p.m. EDT
Wed, August 1, 2012
[ Wed, Aug 01st 2012 ] - Market Wire
Head of European Operations
Tue, July 31, 2012
Mon, July 30, 2012

Isis Pharmaceuticals to Present at the Canaccord Genuity 32nd Annual Growth Conference


//health-fitness.news-articles.net/content/2012/ .. ccord-genuity-32nd-annual-growth-conference.html
Published in Health and Fitness on Thursday, August 9th 2012 at 4:16 GMT by Market Wire   Print publication without navigation


Isis Pharmaceuticals to Present at the Canaccord Genuity 32nd Annual Growth Conference -- CARLSBAD, Calif., Aug. 9, 2012 /PRNewswire/ --

Isis Pharmaceuticals to Present at the Canaccord Genuity 32nd Annual Growth Conference

[ ]

CARLSBAD, Calif., Aug. 9, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: [ ISIS ]), the leader in antisense therapeutics, today announced that management will present a company overview at the Canaccord Genuity 32nd Annual Growth Healthcare Conference on Thursday, August 16, 2012 at 11:00 a.m. ET in Boston.

A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's Web site, [ www.isispharm.com ].  A replay of the presentation will be available on the Isis Web site within 48 hours and will be archived for a limited time.

ABOUT ISIS PHARMACEUTICALS, INC.
Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners.  Isis' broad pipeline consists of 25 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, and cancer.  Isis' partner, Genzyme, plans to commercialize Isis' lead product, KYNAMRO™, in the United States and Europe following regulatory approval.  Isis' patents provide strong and extensive protection for its drugs and technology.  Additional information about Isis is available at [ www.isispharm.com ].

FORWARD-LOOKING STATEMENTS
This press release includes forward-looking statements regarding Isis' business and the therapeutic potential of Isis' technologies and products in development.  Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs, including the planned commercialization of KYNAMRO, is a forward-looking statement and should be considered an at-risk statement.  Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements.  Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis.  As a result, you are cautioned not to rely on these forward-looking statements.  These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2011 and its most recent quarterly report on Form 10-Q, which are on file with the SEC. Copies of these and other documents are available from the Company.

In this press release, unless the context requires otherwise, "Isis," "Company," "we," "our," and "us" refers to Isis Pharmaceuticals and its subsidiaries, including Regulus Therapeutics Inc., its jointly owned subsidiary.

Isis Pharmaceuticals® is a registered trademark of Isis Pharmaceuticals, Inc.  KYNAMRO™ is a trademark of Genzyme Corporation.

SOURCE Isis Pharmaceuticals, Inc.



[ Back to top ]

RELATED LINKS
[ http://www.isispharm.com ]


Publication Contributing Sources